What Селектра Treats: Main Uses and Benefits

Selectra (Escitalopram) is commonly used to help patients cope with disruptive emotional and somatic symptoms associated with primary mood and anxiety disorders. The medication is used to help manage Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) in adults. It is also applicable in contexts marked by increased discomfort for conditions involving Panic Disorder and Social Anxiety Disorder.

---

Symptom Domains and Therapeutic Support

This medication is considered relevant for easing symptoms and providing supportive relief during symptomatic episodes. It is applied in addressing key symptom clusters like persistent sadness or loss of interest, excessive and debilitating worry, and associated symptoms related to systemic imbalance such as fatigue and sleep disturbances. It may support patients during difficult episodes by easing distress and can assist with maintaining functional stability when symptoms interfere with routine activities.

“It is commonly used across conditions presenting with acute episodes and provides support that helps ease the overall symptom burden.”

---

Quick Fact: Managing Excessive Worry

Domain	Application Context	Primary Benefit
Anxiety Disorders	Conditions characterized by periods of heightened symptoms, such as GAD and Panic Disorder.	May help patients cope more steadily with symptom fluctuations, offering supportive relief for tension.

Population Eligibility Rules for Селектра (Escitalopram)

Official regulatory documents define strict criteria for who can and cannot use Escitalopram, based on age, pre-existing conditions, and concurrent medication use.

Absolute Contraindications

Use is strictly prohibited for patients with a known hypersensitivity to escitalopram, citalopram, or any excipients. It is contraindicated for use alongside Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, and concurrently with Pimozide. Additionally, patients with a documented known long QT interval or congenital long QT syndrome must not use this medicine.

Age and Physiological Restrictions

The medicine is primarily approved for adults 18 years and older. Use is generally not recommended in children under 12 and in adolescents for certain indications, as safety and efficacy are not established. For geriatric patients (over 65) and those with mild to moderate hepatic impairment, a reduced maximum dose is required. Use in severe hepatic impairment is not recommended. Caution is also advised during the third trimester of pregnancy and lactation, as the drug is excreted into human milk.

Interactions with other medicines and products

Official regulatory documents define specific drug and substance interaction patterns for Escitalopram (the active ingredient in Selectra).

Contraindicated Combinations

The co-administration of Escitalopram with Monoamine Oxidase Inhibitors (MAOIs), including psychiatric MAOIs, Linezolid, and intravenous Methylene Blue, is strictly contraindicated due to the high risk of Serotonin Syndrome. Co-administration with the antipsychotic Pimozide is also contraindicated due to the potential for serious heart rhythm abnormalities. A mandatory 14-day washout period is required when switching between Escitalopram and a psychiatric MAOI.

Pharmacodynamic and Pharmacokinetic Interactions

Co-use with other serotonergic agents (such as Triptans, Tramadol, and St. John's Wort) increases the risk of Serotonin Syndrome through additive effects. Combining Escitalopram with medications that interfere with hemostasis (e.g., NSAIDs, Warfarin) increases the documented risk of abnormal bleeding.

From a metabolic perspective, CYP2C19 and CYP3A4 inhibitors (like Omeprazole) may increase Escitalopram plasma concentrations. Escitalopram also exerts a modest inhibitory effect on CYP2D6, which may increase the exposure of co-administered drugs like Metoprolol. The co-use of alcohol may increase sedation and impair alertness.

Selective Serotonin Transporter Blockade

Escitalopram acts exclusively on the Serotonin Transporter (SERT), a protein on the presynaptic nerve cell surface, functioning as an inhibitor of Serotonin reuptake. This mechanism is focused on processes involving monoaminergic signaling, differing from mechanisms that involve significant interaction with other systems like histamine receptors or the norepinephrine transporter. This action acutely leads to a sustained elevation of Serotonin (5 -HT) concentration in the synaptic cleft.

The drug is unique for simultaneously binding to two sites on the SERT—the primary site and a secondary allosteric modulatory site—which is theorized to enhance the stability and duration of the inhibition process. Furthermore, as a single S-enantiomer, the mechanism promotes focused pharmacological action at the transporter.

This immediate increase in Serotonin signaling triggers a slower process of neuroadaptation in the central nervous system, involving gradual changes in the sensitivity and density of 5 -HT receptors. This mechanism is critical for establishing a new, stable serotonergic equilibrium across emotional circuits, which is the physiological consequence that shapes the functional outcome of central serotonergic pathways.

Administration Guidelines

Administration of Escitalopram is strictly oral, and the medication is available in film-coated tablets (5 mg, 10 mg, 20 mg strengths) and as an oral solution. It is administered once daily, with no specific requirement for timing relative to meals, meaning it can be taken with or without food, either in the morning or evening. Consistency is required, and doses should be taken at the same time each day.

Standard Dosing Regimens

The standard protocol for adults begins with an initial dose of 10 mg once daily. The dosage may be increased to a maximum recommended dose of 20 mg once daily, though this adjustment should occur after a minimum interval of one week of treatment to allow for proper titration.

Population Group	Starting Dose	Maximum Daily Dose
Adults (Standard)	10 mg once daily	20 mg once daily
Older Adults (≥65 years)	5 mg once daily	10 mg once daily
Hepatic Impairment	Not exceeding 10 mg once daily	10 mg once daily

In cases of a missed dose, it is generally recommended to take the dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be resumed. Double doses are not permitted. Treatment is typically long-term, and when discontinuation is planned, the dose must be gradually reduced over a period of at least one to two weeks, rather than stopped abruptly, to follow clinical protocols.

Research Evidence / Overview of Studies for Селектра

This overview describes the types of clinical studies that have been conducted for Escitalopram (Селектра) and what the regulated evidence suggests, without offering clinical guidance or predicting individual results.

Evidence for Use in Major Depressive Disorder (MDD)

The research for Major Depressive Disorder (MDD) relies on a large volume of Randomized Controlled Trials (RCTs) and scientific reviews known as meta-analyses. These studies explored how symptoms change over defined observation periods. Research examined measured outcomes related to physical symptoms and standardized assessments of functional status.

Studies reported data on symptom scores measured over intervals typically lasting six to eight weeks. Comparative trials have also been conducted, examining measured outcomes when Escitalopram was observed against placebo and other medicines in the same class. Long-term outcomes in adolescents are not well-characterized beyond the initial study periods, and evidence is limited regarding specific, less common forms of depression.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Research investigated Generalized Anxiety Disorder (GAD) through multiple short-term, placebo-controlled RCTs and studies focusing on longer-term maintenance. These studies examined measured outcomes related to general anxiety and outcomes describing episodic symptom changes in both adult and pediatric populations.

Long-term research observed outcomes over defined time intervals of up to 24 weeks, exploring outcomes related to the stability of measured symptom scores in patients who initially responded. Long-term effects for GAD in pediatric and adolescent populations are not well-characterized, and the consistency of findings among different research protocols is continually monitored.

Evidence for Use in Panic Disorder and Social Anxiety Disorder

Clinical trials were used in research exploring short-term symptom changes for both Panic Disorder and Social Anxiety Disorder. These studies primarily focused on adults, monitoring outcomes linked to physiological strain or stress.

For Panic Disorder, research examined measured outcomes related to the frequency of acute episodes. For Social Anxiety Disorder, studies explored measured changes in social fear and avoidance behaviors. For both conditions, the evidence base is more limited than for MDD and GAD, and long-term outcomes are not as extensively characterized.

Common questions about Селектра (FAQ)

Q: Можно ли прекратить прием Селектра, если стало лучше?

A: Official information emphasizes that treatment should not be stopped suddenly. When discontinuation is planned, regulatory documents advise a gradual reduction in the dose over a period of one to two weeks or longer to minimize the risk of withdrawal symptoms. Any decision to stop the medicine or change the dosage schedule falls within the purview of a healthcare professional.

Q: Можно ли принимать Селектра во время беременности?

A: Official warnings exist regarding potential risks to the newborn if this medicine is used during the third trimester of pregnancy, including symptoms of poor adaptation. The general guidance is that the drug should only be used during pregnancy if the potential benefit is believed to justify the potential risk to the fetus. Guidance on the appropriate course of action, based on the specific circumstances, is provided by a medical professional.

Q: Как Селектра влияет на сон?

A: Clinical studies have reported both insomnia (difficulty sleeping) and somnolence (drowsiness or sleepiness) as common side effects. This means the medicine may affect sleep patterns differently for various people. Changes to sleep patterns are commonly reported and should be acknowledged in discussions with a healthcare provider.

Q: Правда ли, что в начале приема Селектра состояние может ухудшиться?

A: Official safety warnings describe an increased risk of suicidal thinking and behavior, particularly in young adults and adolescents, and note that this risk is greatest during the initial months of treatment or following dosage changes. Additionally, an increase in general anxiety is sometimes reported at the start of treatment, which regulatory sources suggest often improves within the first two weeks as the body adjusts.

Q: Что такое синдром отмены при прекращении приема Селектра?

A: Withdrawal syndrome, or discontinuation syndrome, refers to a collection of symptoms that may appear if an antidepressant is abruptly stopped or the dosage is reduced too quickly. Regulatory sources describe typical manifestations such as dizziness, nausea, sensory disturbances (often called 'brain zaps'), and anxiety. Gradual dose reduction is the established method to minimize the risk of these effects.

Q: Есть ли специальная информация о Селектра для пожилых людей?

A: Yes, official regulatory documents advise a lower maximum daily dose for patients over the age of 65. Special monitoring is also recommended for this age group due to an elevated risk of hyponatremia (a low level of sodium in the blood), which is a specific safety concern noted in the official labeling.

Q: Нужна ли коррекция дозы Селектра при проблемах с печенью или почками?

A: Official guidelines recommend a lower maximum dose for patients with mild to moderate hepatic (liver) impairment. For those with mild or moderate renal (kidney) impairment, dose adjustment is generally not required, but caution is advised in cases of severe kidney impairment.

Q: Чем Селектра отличается от других похожих лекарств?

A: The active substance, Escitalopram, is chemically described in official sources as the purified S-enantiomer (active form) of the older drug Citalopram. This characteristic is cited as giving it a highly selective action in inhibiting serotonin reuptake, which is the mechanism that differentiates it from older or less selective agents.

Q: Через какое время начинает действовать Селектра?

A: Official clinical studies indicate that initial physical symptoms, such as improvements in sleep, energy, or appetite, may begin to be noticeable within the first 1 to 2 weeks. However, the full therapeutic benefit on mood and general symptoms may require up to 6 to 8 weeks of continuous treatment.

Q: Влияет ли Селектра на способность управлять автомобилем?

A: Regulatory documents include warnings that this medicine may affect cognitive and motor functions (mental alertness and coordination). Regulatory documents recommend caution be exercised regarding activities requiring alertness, such as driving or operating heavy machinery, until an individual knows how the medicine affects their cognitive and motor functions.

Q: Может ли Селектра взаимодействовать с БАДами или витаминами?

A: Official warnings specifically prohibit concurrent use with the herbal supplement St. John's Wort due to the increased risk of serotonin-related side effects. The disclosure of all supplements, herbs, and vitamins to a healthcare provider is noted in official guidance, as comprehensive safety data is not available for all possible combinations.

Q: Что известно о долгосрочных эффектах приема Селектра?

A: Clinical trial data suggest the medicine offers a preventative benefit against the return of depressive symptoms when taken for extended periods. Nevertheless, official product information recommends that physicians should periodically re-evaluate the long-term usefulness of the medicine for each individual patient.

Q: Какие ощущения считаются нормальными в первые дни приема Селектра?

A: In the initial phase of treatment, it is common to temporarily experience a slight increase in some side effects, such as nausea, headaches, or anxiety. Official sources suggest these effects usually lessen or disappear as the body adapts to the medicine over the first couple of weeks.

Q: Существуют ли исследования об эффективности Селектра для детей?

A: The medicine is approved by the FDA for treating major depressive disorder in adolescents aged 12–17 years. However, official regulatory bodies in Europe often advise caution in the pediatric population due to a lack of long-term data regarding the effects on growth, development, and maturation.

Q: Селектра влияет только на настроение или на что-то еще?

A: While the primary purpose is to modulate mood and anxiety, the active substance acts systemically throughout the body. This is confirmed by the wide range of documented side effects that affect the gastrointestinal, nervous, reproductive, and other bodily systems.

Q: Влияет ли Селектра на артериальное давление?

A: Selective Serotonin Reuptake Inhibitors (SSRIs) like this medicine are generally considered less likely to cause a significant rise in blood pressure compared to some other antidepressant classes. However, due to its influence on physiological systems, caution may be necessary for patients with pre-existing hypertension.

Q: Может ли Селектра влиять на аппетит?

A: Clinical trial data indicate that the medicine may cause decreased appetite as a less common side effect. Conversely, an improvement in a patient’s overall condition can sometimes lead to an increase in appetite as a depressive symptom resolves.

Q: Почему Селектра нельзя использовать для лечения биполярного расстройства?

A: Official documents warn that the use of antidepressants, including Selectra, may trigger a manic or hypomanic episode in individuals with undiagnosed or existing bipolar disorder. For this reason, official sources recommend the medicine be used cautiously, and treatment should be stopped if a manic phase develops.

Q: Что известно о взаимодействии Селектра с препаратами от мигрени?

A: Official regulatory warnings exist concerning the co-administration of Selectra with anti-migraine medications known as Triptans. This combination is cautioned against as it may increase the risk of developing Serotonin Syndrome due to the combined serotonergic effects of the two drug classes.

Q: Влияет ли Селектра на результаты анализов крови?

A: Yes, official labeling reports that the medicine can potentially cause a decrease in blood sodium levels, known as hyponatremia. This condition is detected via a blood test. Monitoring of sodium levels may be recommended by a physician, particularly for older adults or those taking diuretics.

Q: Как долго нужно ждать, чтобы понять, подходит ли мне Селектра?

A: Based on clinical research, a full therapeutic assessment to determine the suitability of the medicine is typically performed after 6 to 8 weeks of treatment. Dosage adjustments, if required, should be done with a minimum time interval to allow the body to properly adapt.

Q: Может ли Селектра помочь при тревожности без депрессии?

A: Yes, regulatory authorities have provided official approval (indication) for the use of the medicine in treating Generalized Anxiety Disorder (GAD) in adults. This means the medicine is specifically recognized for its role in managing anxiety, independent of major depressive disorder.

Q: Какие есть официальные источники информации о Селектра?

A: Authoritative sources include documents published by government regulatory bodies responsible for drug oversight. These include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA/SmPC), and national institutes of health (such as NIH/MedlinePlus), which provide factual and non-promotional drug details.

Q: Возможно ли взаимодействие Селектра с травяными чаями?

A: Official warnings specifically exist for the herbal remedy St. John's Wort due to its potential to increase the risk of Serotonin Syndrome. Discussions with a healthcare professional regarding the use of all herbal products are noted in guidance.

Q: Что делать, если на фоне приема Селектра чувствуется усталость?

A: Official clinical data notes that somnolence (drowsiness) and fatigue are common side effects reported during clinical trials. If this feeling is persistent, it is a recognized topic for discussion with a medical provider, particularly as an adjustment to the timing of the dose may sometimes be considered.

Escitalopram (Selectra) must be stored and disposed of according to strict conditions defined in regulatory documentation. The product must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C (86 F). Storage must ensure protection from excessive heat, moisture, and light [1.1, 2.1].

Storage Restriction	Requirement
Container Integrity	Keep in the original container, tightly closed [3.1].
Stability	Oral solution must be discarded 2 months after opening [1.3].
Prohibited Environment	The oral solution must not be frozen [3.1].
Safety	Store out of the sight and reach of children and pets [1.2].

Expired or unused Escitalopram must be disposed of safely through drug take-back programs or by following the instructions provided by local regulations, and should not be discarded via wastewater [3.2].